Oncotelic Therapeutics (OTCQB: OTLC) has launched an artificial intelligence-powered GMP manufacturing services platform that integrates its proprietary PDAOAI architecture, digital batch records, and intelligent robotics developed with partner TechForce Robotics. The platform is designed to address a critical bottleneck in biotechnology: the transition from discovery to clinical manufacturing.
For many emerging biotechnology companies, the path from promising science to clinical execution is hindered by the need for good manufacturing practices (GMP), regulatory documentation, batch records, quality systems, and scalable production. Building or accessing such infrastructure is slow, expensive, and operationally overwhelming for smaller firms, including virtual biotechs, university labs, and lean startups.
Oncotelic’s new platform targets these companies, as well as contract development and manufacturing organizations (CDMOs), cell and gene therapy developers, and radiopharmaceutical manufacturers that cannot justify building full GMP infrastructure in-house. The same AI-GMP capabilities are already operational inside Oncotelic’s SAPU manufacturing base, positioning the launch as both a pipeline accelerator and a potential new revenue line.
According to the company, the platform leverages AI to streamline manufacturing processes, reduce errors, and ensure compliance with regulatory standards. Digital batch records and intelligent robotics are key components, enabling real-time monitoring and automation. The partnership with TechForce Robotics brings expertise in robotics integration, enhancing the platform’s scalability and efficiency.
This move comes as the biotech industry faces increasing pressure to reduce costs and accelerate timelines. By offering AI-powered GMP services, Oncotelic aims to help smaller companies overcome the manufacturing hurdle without massive capital investment. The platform could also allow Oncotelic to generate revenue by servicing external clients, leveraging its existing infrastructure.
The launch is significant for the broader industry as it demonstrates how artificial intelligence can be applied to manufacturing challenges, potentially setting a precedent for other companies. For leaders in business and technology, this development highlights the growing intersection of AI and biopharmaceutical manufacturing, which could lead to faster development of therapies and lower costs.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and high-unmet-need indications. The company’s newsroom can be accessed at https://ibn.fm/OTLC for the latest updates.
